AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 71 min read$SOPH

Menu Philippe sold $60K of SOPH

Menu Philippe (Chief Medical Officer) sold 7,394 shares of SOPHiA GENETICS SA (SOPH) at $8.13 on 2026-10-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Menu Philippe
Published Oct 7, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 8:05 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SOPH
Neutral
medium confidence
Mentioned
$SOPH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHNeutralLow
01

Why it matters

The transaction is a primary source filing but the monetary value is modest, limiting market impact.

02

Market read

A small insider sell that is unlikely to move the stock significantly, but worth noting for compliance monitoring.

03

What to watch

Pre‑arranged 10b5‑1 plan and the officer's remaining large stake mitigate negative signal.

Relevance 2/10Novelty 2/10Timing: filing date 2026‑10‑07

Background

SEC Form 4 filing discloses an insider transaction by SOPHiA GENETICS' Chief Medical Officer.

Company-level read

Ticker impact

$SOPHNeutralMedium confidence
Context

Chief Medical Officer Philippe Menu sold 7,394 shares for $60,099 via a 10b5‑1 plan, reducing his holding to 200,993 shares.

Expected impact

likely slight downward pressure as the market prices the insider sell

Evidence & confidence

A $60k sale by a senior officer is a routine 10b5‑1 transaction; the amount is small relative to market cap, so impact is limited.

Market effects

Sector

minor effect on healthcare data‑analytics sector

Regional

European biotech market

Global

low

Counterpoint

What could challenge this read

The sale may be unrelated to company fundamentals and could be a routine liquidity move.

Key entities

  • company
    SOPHiA GENETICS SA

    Swiss biotech firm listed on NASDAQ under SOPH.

  • person
    Menu Philippe

    Chief Medical Officer of SOPHiA GENETICS.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SOPH insider trading history →

Related articles

AUG 11
$SOPHMedAI 8/10

SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

fool.com6 min
AUG 4
$SOPHHighAI 9/10

SOPHiA GENETICS Reports Second Quarter 2026 Results

SOPHiA GENETICS (Nasdaq: SOPH) reported Q2 2026 revenue of $23.3 million, up 27% year over year, with gross margin of 64.6% reported and 72.1% adjusted. Net loss was $22.4 million and adjusted EBITDA loss was $8.8 million, improving 27%. The company raised 2026 revenue guidance to $94-$96 million and signed AstraZeneca companion diagnostic programs.

prnewswire.com6 min
AUG 4
$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q2 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Second Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, August 4, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the second quarter ended June 30,

SEC EDGAR 6-K2 min
AUG 4
$SOPHMed

SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies

SOPHiA GENETICS (NASDAQ: SOPH) said it entered a multi-year collaboration with AstraZeneca to develop, validate, and deploy two companion diagnostics for precision oncology therapies. SOPHiA will advance its Solid Tumor decentralized CDx and develop a Hematological Oncology application for blood cancer. The programs aim to support commercialization of AstraZeneca therapies.

finanznachrichten.de4 min